Table 1. Survival Analysis According to Clinicopathologic and Operative Findings.

	DFS					OS
	Univariate		Multivariate			Univariate		Multivariate
	Months	p value	Exp(β)	95% CI	p value	Months	p value	Exp(β)	95% CI	p value
Age, yr
<63 (n=25)/≥63 (n=25)	13.7/11.1	0.333				28.6/33.2	0.982
Sex
Male (n=30)/Female (n=20)	12.5/10.3	0.915				33.2/27.9	0.765
CA19-9, U/mL
≤109 (n=24)/>109 (n=25)	18.0/10.2	0.243				35.8/21.7	0.340
Tumor size, cm
<3.5 (n=27)/≥3.5 (n=23)	13.7/8.4	0.134				42.1/18.9	0.031
Yonsei criteria		0.021					0.001
Satisfying (n=23)	23.6					65.7
Not satisfying (n=27)	10.3					20.2		2.59	1.151–5.829	0.021
NCCN resectability
Resectable (n=44)/Borderline (n=6)	12.5/10.2	0.475				28.6/65.7	0.330
pN stage
N0 (n=27)/N1 (n=23)	13.7/10.2	0.094				37.2/21.2	0.143
Number of metastatic LNs		<0.001					0.003
<2 (n=36)	15.1
≥2 (n=11)	7.9		3.354	1.582–7.110	0.002	37.2		2.536	1.083–5.936	0.032
LN ratio in N1 stage						18.9
<0.09 (n=11)/> 0.09 (n=12)	13.5/4.6	0.352				22.0/18.9	0.623
Combined organ resection
No (n=38)/Yes (n=12)	13.7/7.27	0.020				37.2/13.3	0.008
Differentiation
Well (n=11)	18.7					42.1
Moderate (n=34)	12.5					28.6
Poor (n=4)	3.2					13.3
Undifferentiation (n=1)	8.0					39.3
Lymphovascular invasion
No (n=37)/Yes (n=10)	12.2/18.0	0.676				28.6/21.2	0.865
Perineural invasion
No (n=24)/Yes (n=23)	12.2/12.8	0.849				22.0/33.2	0.444
Transfusion		0.005					0.028
No (n=37)	18.0					39.3
Yes (n=13)	6.6		2.615	1.248–5.482	0.011	20.28

DFS, disease-free survival; OS, overall survival; CI, confidence interval; NCCN, National Comprehensive Cancer Network; LNs, lymph nodes.